Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-03-08
2011-03-08
Bristol, Lynn (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C514S006900, C514S012200
Reexamination Certificate
active
07901879
ABSTRACT:
The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.
REFERENCES:
patent: 4977137 (1990-12-01), Nichols et al.
patent: 5198419 (1993-03-01), Ando et al.
patent: 5571691 (1996-11-01), Conneely et al.
patent: 5571697 (1996-11-01), Conneely et al.
patent: 5571896 (1996-11-01), Conneely et al.
patent: 5766939 (1998-06-01), Conneely et al.
patent: 5849881 (1998-12-01), Conneely et al.
patent: 5955316 (1999-09-01), Conneely et al.
patent: 6080559 (2000-06-01), Conneely et al.
patent: 6100054 (2000-08-01), Conneely et al.
patent: 6111081 (2000-08-01), Conneely et al.
patent: 6228614 (2001-05-01), Conneely et al.
patent: 6333311 (2001-12-01), Nuijens et al.
patent: 6399570 (2002-06-01), Mann
patent: 6635447 (2003-10-01), Conneely et al.
patent: 6890902 (2005-05-01), Svendsen et al.
patent: 2003/0022821 (2003-01-01), Svenden et al.
patent: 2003/0096736 (2003-05-01), Kruzel et al.
patent: 2003/0105006 (2003-06-01), Mann
patent: 2003/0190303 (2003-10-01), Kimber et al.
patent: 2004/0009896 (2004-01-01), Glynn et al.
patent: 2004/0082504 (2004-04-01), Varadhachary et al.
patent: 2004/0142037 (2004-07-01), Engelmayer et al.
patent: 2005/0064546 (2005-03-01), Conneely et al.
patent: 2005/0075277 (2005-04-01), Varadhachary et al.
patent: 2010/0137208 (2010-06-01), Varadhachary et al.
patent: 0730868 (1996-09-01), None
patent: 63051337 (1988-03-01), None
patent: 05186368 (1993-07-01), None
patent: 2001-504447 (1999-02-01), None
patent: 2002-519332 (1999-06-01), None
patent: 2000229881 (2000-08-01), None
patent: WO-9806425 (1998-02-01), None
patent: 9833509 (1998-08-01), None
patent: WO-9844940 (1998-10-01), None
patent: WO-0203910 (2002-01-01), None
patent: WO-2006/054908 (2006-05-01), None
McColl GJ. Med. J. Aust. 175: S108-S111, 2001; referenced as printout pp. 1-8.
Gordon KB et al. J. Am. Acad. Dermatol. 54(3): S85-S91, 2006.
Smorenburg et al. European Journal of Cancer 37: 2310-2323, 2001.
Kuhara T et al. Nutrition and Cancer 38(2): 192-199, 2000.
Ogura T et al. Blood 98(7): 2101-2107, 2001.
Inaba K et al. Proc. Natl. Acad. Sci. USA 90: 3038-3042, 1993.
Walter KA et al. Neurosurgery 37(6): 1129-1145, 1995.
Gustalla et al. British Journal of Cancer89: S16-S22, 2003.
Lebwohl et al. European Journal of Cancer 34(10): 1522-1534, 1998.
Griffiths CEM et al. British Journal of Dermatology 144: 715-725, 2001.
Krzakowski M. Lung Cancer 34: S159-S163, 2001.
Voskoglou-Nomikos et al. (Clin. Can. Res. 9:4227-4239 (2003)).
Definition of “Alimta”.
Talmadge et al. (Am. J. Pathol 170(3):793-804 (2007)).
Ushida et al (Japn. J. Cancer Res. 90: 262-267 (Mar. 1999).
Loughlin et al. (Can. 59(3):566-571 (1987); Abstract).
U.S. Appl. No. 10/733,621, Agennix Incorporated.
U.S. Appl. No. 10/732,429, Agennix Incorporated.
U.S. Appl. No. 10/844,865, Agennix Incorporated.
U.S. Appl. No. 10/728,521, Agennix Incorporated.
U.S. Appl. No. 10/862,213, Agennix Incorporated.
U.S. Appl. No. 10/728,275, Agennix Incorporated.
Amouric et al, “Effect of Lactoferrin on the Growth of a Human Colon Adenocarcinoma Cell Line—Comparison with Transferrin,” in Vitro vol. 20 No. 7, Jul. 1984, pp. 543-548.
Barresi et al, “Lactoferrin in Benign Hypertrophy and Carcinomas of the Prostatic Gland,” Virchows Archiv (Pathol Anat) 403; 1984, pp. 59-66.
Shau et al, “Modulation of Natural Killer and Lymphokine-activated Killer Cell Cytotoxicity by Lactoferrin,” Journal of Leukocyte Biology vol. 51, Apr. 1992, pp. 343-349.
Brock et al, “Interaction of LActoferrin with Mononuclear and Colon Carcinoma cells,” Lactoferrin—Structure and Function, T.W. Hutches, S.V. Rumball and B. Lonnerdal. New York, Plenum PRess: pp. 157-169.
Bezault et al, “Human Lactoferrin Inhibits Growth of Solid Tumors and Development of Experimental Metastases in Mice,” Cancer Research 54, May 1, 1994, pp. 2310-2312.
Sekine et al, “Inhibition of Azoxymethane-initiated Colon Tumor by Bovine Lactoferrin Administration in F344 Rats,” Jpn. J. Cancer Res. 88, Jun. 1997, pp. 523-526.
Yoo et al, “Bovine Lactoferrin and Lactoferricin, a Peptide Derived from Bovine Lactoferrin, Inhibit Tumor Metastasis in mice,” Jpn. J. Cancer Res. 88, Feb. 1997, pp. 184-190.
Tsuda et al, Inhibition of Azoxymethane Initiated Colon Tumor and Aberrant Crypt FOCI Development by Bovine Lactoferrin Administration in F344 Rats, Advances in Lactoferrin research, edited by Spik et al, Plenum Press, New York, 1998, pp. 273-283.
Damiens et al, “Effects of Human Lactoferrin on NK Cell Cytotoxicity Against Haematopoietic and Epithelial Tumour Cells,” Biochimica et Biophysica Acta 1402, 1998, pp. 277-287.
Ushida et al, “Inhibitory Effects of Bovine Lactoferrin on Intestinal Polyposis in the Apc Mouse,” Cancer Letters 134, 1998, pp. 141-145.
Yoo et al, “Bovine Lactoferrin and Lactoferricin Inhibit Tumor Metastasis in Mice,” Advances in Lactoferrin Research, Chapter 35, Plenum Press, New York, 1998, pp. 285-291.
Sakamoto, N., “Antitumor Effect of Human Lactoferrin against Newly Establishes Human Pancreatic Cancer Cell Line SPA,” Gan to Kagaku Ryoho, Aug. 1998 25(10), pp. 1557-1563.
Ushida et al, “Possible Chemopreventive Effects of Bovine Lactoferrin on Esophagus and Lung Carcinogenesis in the Rat,” Jpn. J. Cancer Res. 90, Mar. 1999, pp. 262-267.
Damiens et al, “Lactoferrin Inhibits G1 Cyclin-Dependent Kinases During Growth Arrest of Human Breast Carcinoma Cells,” Journal of Cellular Biochemistry 72, 1999, pp. 486-498.
Iigo et al, “Inhibitory Effects of Bovine Lactoferrin on Colon Carcinoma 26 Lung Metastasis in Mice,” Clinical & experimental Metastasis 17, 1999, pp. 35-40.
Masuda et al, “Chemopreventive Effects of Bovine Lactoferrin on N-Butyl-N (4-hydroxybutyl) Nitrosamine-Induced Rat Bladder Carcinogenesis,” Jpn. J. Cancer Res. 91, Jun. 2000, pp. 582-588.
Tanaka et al, “Bovine Lactoferrin Inhibits Rat Tongue Carcinogenesis,” Elsevier Sciences B.V. Lactoferrin: Structure, Function and Applications 2000, pp. 401-411.
Tsuda et al, “Milk and Dairy Products in Cancer Prevention: Focus on Bovine Lactoferrin,” Elsevier Science B.V.—Mutation Research 462, 2000, pp. 227-233.
Teng et al, “Lactoferrin Gene: Methylation, Expression and Cancer,” Elseiver Science B.V.—Lactoferrin: Structure, Function and Application, 2000, pp. 247-255.
Kuhara et al, “Orally Administered Lactoferrin Exerts an Antimetastatic Effect and Enhances Production of IL-18 in the Intestinal Epithelium,” Nutrition and Cancer, vol. 28 No. 2, 2000, pp. 192-199.
Tsuda et al, “Prevention of Carcinogenesis and Metastasis by Dietary Bovine Lactoferrin,” Elsevier Sciences B.V.—Lactoferrin: Structure, Function and Applications, 2000, pp. 389-399.
Tsuda et al, “Prevention of Colon Carcinogenesis and Carcinoma Metastasis by Orally Administered Bovine Lactoferrin in animals,” BioFactors 12, 2000, pp. 83-88.
Wang et al, “Activation of Intestinal Mucosal Immunity in Tumor-bearing Mice by Lactoferrin,” Jpn. J. Cancer Res. 91, Oct. 2000, pp. 1022-1027.
Norby et al,“Orally Administered Bovine Lactoferrin Systemically Inhibits VEGF 165—Mediated Angiogenesis in the Rat,” Int. j. Cancer 91, 2001, pp. 236-240.
Varadhachary et al., “Intratumoral Injection of human Recombinant Lactoferrin Inhibits the Growth of Human Tumors Implanted in Athymic Nude Mice,” www.asco.org, Abstract No. 1875, 2002.
Varadhachary et al, “Recombinant Human Lactoferrin, a novel oral Anti-Cancer Drug,” www.asco.org, Abstract No. 934, 2003.
van Belzen, nico, “The Role of Lactoferrin in Cancer Prevention,” Sciences Des Aliments, 22, 2002, pp. 461-468.
Tsuda et al, “Cancer Prevention by Bovine Lactoferrin and Underlying Mechanisms—a Review of E
Barsky Rick
Pericle Federica
Petrak Karel
Varadhachary Atul
Wang Yenyun
Agennix Incorporated
Bristol Lynn
Fulbright & Jaworski L.L.P.
LandOfFree
Lactoferrin in the treatment of malignant neoplasms and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lactoferrin in the treatment of malignant neoplasms and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lactoferrin in the treatment of malignant neoplasms and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2725318